わが国のPlateletapheresisの現状と将来

概要

論文の詳細を見る
Ten years have passed since the Japanese Red Cross adopted new blood collection standards in 1986. Since then, the blood programme has undergone significant changes, not the least of which has been a shift from the collection of whole blood to the collection of individual blood components. With this shift, the clinical efficacy of apheresis-derived single donor platelets has been especially well appreciated. At the same time, apheresis equipment manufacturers have vied to introduce devices capable of highly efficient collection of platelet concentrates with few contaminating leucocytes. These advances have played an important role in the reduction of alloimmunization, virus infection, and other non-hemolytic transfusion reactions. The most prominent apheresis devices available include MCS, Multi, CCS (haemonetics), CS-3000 plus, Amicus (Baxter), Spectra, Spectra LRS turbo (COBE), and AS-104 (Fresenius). We have explored each machines characteristics, trying to maximize platelet efficiencies while controlling white blood ceil contamination. We have also pursued improvements in machine useability and donor management using these devices. Lastly, jn an attempt to further reduce post-transfusion side effects, we have obtained good results in our clinical evaluation of prestorage leukocyte-reduced platelet concentrates.
日本アフェレシス学会の論文
1998-02-28